Research Programs Unit, Translational Immunology, Haartmaninkatu 3 (PL 21) 00014, and Medicum, University of Helsinki, Helsinki, Finland.
Department of Computer Science, Aalto University, Espoo, Finland.
Cancer Med. 2023 Jun;12(12):13486-13496. doi: 10.1002/cam4.6002. Epub 2023 Apr 28.
The number of mutations in cancer cells is an important predictor of a positive response to cancer immunotherapy. It has been suggested that the neoantigens produced by these mutations are more immunogenic than nonmutated tumor antigens, which are likely to be protected by immunological tolerance. However, the mechanisms of tolerance as regards tumor antigens are incompletely understood.
Here, we have analyzed the impact of thymic negative selection on shared T-cell receptor (TCR) repertoire associated with the recognition of either mutated or nonmutated tumor antigens by comparing previously known TCR-antigen-pairs to TCR repertoires of 21 immunologically healthy individuals.
Our results show that TCRα chains associated with either type of tumor antigens are readily generated in the thymus, at a frequency similar to TCRα chains associated with nonself. In the peripheral repertoire, the relative clone size of nonself-associated chains is higher than that of the tumor antigens, but importantly, there is no difference between TCRα chains associated with mutated or nonmutated tumor antigens.
This suggests that the tolerance mechanisms protecting nonmutated tumor antigens are non-deletional and therefore potentially reversible. As unmutated antigens are, unlike mutations, shared by a large number of patients, they may offer advantages in designing immunological approaches to cancer treatment.
癌细胞的突变数量是癌症免疫治疗反应阳性的一个重要预测指标。据推测,这些突变产生的新抗原比非突变肿瘤抗原更具免疫原性,而这些非突变肿瘤抗原很可能受到免疫耐受的保护。然而,关于肿瘤抗原的耐受机制尚未完全了解。
在这里,我们通过将先前已知的 TCR-抗原对与 21 名免疫健康个体的 TCR 谱进行比较,分析了胸腺阴性选择对识别突变或非突变肿瘤抗原的共享 T 细胞受体(TCR)谱的影响。
我们的结果表明,与突变或非突变肿瘤抗原相关的 TCRα 链在胸腺中以与非自身相关的 TCRα 链相似的频率轻易产生,在外周谱中,非自身相关链的相对克隆大小高于肿瘤抗原,但重要的是,与突变或非突变肿瘤抗原相关的 TCRα 链之间没有差异。
这表明保护非突变肿瘤抗原的耐受机制是非删除性的,因此可能是可逆的。由于未突变的抗原不像突变那样被大量患者共享,因此它们在设计癌症治疗的免疫方法方面可能具有优势。